Repligen (NASDAQ:RGEN) Shares Gap Up to $210.95

Shares of Repligen Co. (NASDAQ:RGEN) gapped up before the market opened on Thursday . The stock had previously closed at $210.95, but opened at $217.96. Repligen shares last traded at $206.91, with a volume of 448 shares changing hands.

Several equities research analysts have weighed in on the company. Exane BNP Paribas assumed coverage on Repligen in a research report on Thursday, October 14th. They issued an “outperform” rating and a $330.00 target price on the stock. Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $285.00 target price on the stock in a research report on Tuesday, December 7th. Craig Hallum increased their target price on Repligen from $258.00 to $368.00 and gave the stock a “buy” rating in a research report on Monday, September 27th. BNP Paribas assumed coverage on Repligen in a research report on Thursday, October 14th. They issued an “outperform” rating and a $330.00 target price on the stock. Finally, KeyCorp increased their target price on Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a research report on Friday, September 17th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Repligen presently has an average rating of “Buy” and a consensus target price of $312.88.

The company has a market cap of $10.69 billion, a P/E ratio of 92.03 and a beta of 0.78. The company has a 50 day moving average price of $256.43 and a 200-day moving average price of $258.60.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, October 28th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. Repligen had a return on equity of 9.81% and a net margin of 20.06%. The company had revenue of $178.22 million during the quarter, compared to analysts’ expectations of $163.97 million. During the same quarter in the prior year, the business posted $0.40 earnings per share. The company’s revenue for the quarter was up 89.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Repligen Co. will post 2.9 earnings per share for the current year.

In related news, CEO Anthony Hunt sold 17,355 shares of the firm’s stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $276.85, for a total transaction of $4,804,731.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas F. Ryan, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 4th. The shares were sold at an average price of $288.00, for a total value of $288,000.00. The disclosure for this sale can be found here. Insiders have sold 22,400 shares of company stock valued at $6,296,277 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System boosted its position in shares of Repligen by 1.5% in the 4th quarter. Louisiana State Employees Retirement System now owns 13,200 shares of the biotechnology company’s stock valued at $3,496,000 after purchasing an additional 200 shares during the period. First Hawaiian Bank acquired a new position in shares of Repligen in the 4th quarter valued at $829,000. Moors & Cabot Inc. acquired a new position in shares of Repligen in the 3rd quarter valued at $188,000. CLARET ASSET MANAGEMENT Corp acquired a new position in shares of Repligen in the 3rd quarter valued at $212,000. Finally, Colony Group LLC acquired a new position in shares of Repligen in the 3rd quarter valued at $320,000. Institutional investors and hedge funds own 84.96% of the company’s stock.

About Repligen (NASDAQ:RGEN)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Story: Cost Basis

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.